Kempner Capital Management Has Cut Teva Phrm Ind LTD Adr (TEVA) Stake By $2.37 Million; Coastway Bancorp (CWAY)’s Sentiment Is 0.56

Coastway Bancorp, Inc. (NASDAQ:CWAY) Logo

Coastway Bancorp Inc (CWAY) investors sentiment decreased to 0.56 in 2017 Q4. It’s down -1.94, from 2.5 in 2017Q3. The ratio has dropped, as 5 investment managers started new and increased equity positions, while 9 sold and reduced their holdings in Coastway Bancorp Inc. The investment managers in our database now possess: 1.57 million shares, up from 1.56 million shares in 2017Q3. Also, the number of investment managers holding Coastway Bancorp Inc in top ten equity positions increased from 0 to 2 for an increase of 2. Sold All: 2 Reduced: 7 Increased: 4 New Position: 1.

Kempner Capital Management Inc decreased Teva Phrm Ind Ltd Adr (TEVA) stake by 63.06% reported in 2017Q4 SEC filing. Kempner Capital Management Inc sold 131,773 shares as Teva Phrm Ind Ltd Adr (TEVA)’s stock declined 11.04%. The Kempner Capital Management Inc holds 77,184 shares with $1.46 million value, down from 208,957 last quarter. Teva Phrm Ind Ltd Adr now has $18.12 billion valuation. The stock increased 0.62% or $0.11 during the last trading session, reaching $17.82. About 8.38M shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 49.50% since April 22, 2017 and is downtrending. It has underperformed by 61.05% the S&P500.

Analysts await Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report earnings on May, 10. They expect $0.62 EPS, down 39.81% or $0.41 from last year’s $1.03 per share. TEVA’s profit will be $630.47M for 7.19 P/E if the $0.62 EPS becomes a reality. After $0.91 actual EPS reported by Teva Pharmaceutical Industries Limited for the previous quarter, Wall Street now forecasts -31.87% negative EPS growth.

Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 8 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma has $86 highest and $8 lowest target. $28.88’s average target is 62.07% above currents $17.82 stock price. Teva Pharma had 150 analyst reports since July 21, 2015 according to SRatingsIntel. On Wednesday, July 29 the stock rating was reinitiated by Morgan Stanley with “Overweight”. Cantor Fitzgerald upgraded the stock to “Hold” rating in Friday, December 22 report. As per Monday, July 27, the company rating was maintained by Maxim Group. The firm has “Hold” rating by Oppenheimer given on Wednesday, October 4. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Hold” rating given on Wednesday, August 30 by Cantor Fitzgerald. As per Monday, October 31, the company rating was upgraded by Credit Suisse. The company was maintained on Thursday, June 22 by Cantor Fitzgerald. RBC Capital Markets maintained it with “Outperform” rating and $85 target in Wednesday, July 29 report. The firm earned “Buy” rating on Friday, April 20 by Mizuho. Mizuho maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Wednesday, November 29 with “Hold” rating.

Clover Partners L.P. holds 7.47% of its portfolio in Coastway Bancorp, Inc. for 370,100 shares. Seidman Lawrence B owns 214,904 shares or 3.48% of their US portfolio. Moreover, Maltese Capital Management Llc has 0.65% invested in the company for 410,000 shares. The Virginia-based Fj Capital Management Llc has invested 0.32% in the stock. Salzhauer Michael, a New York-based fund reported 10,000 shares.

The stock increased 0.18% or $0.05 during the last trading session, reaching $27.3. About 11,374 shares traded. Coastway Bancorp, Inc. (CWAY) has risen 61.54% since April 22, 2017 and is uptrending. It has outperformed by 49.99% the S&P500.

Coastway Bancorp, Inc. (NASDAQ:CWAY) Institutional Positions Chart